FLT3LG and neoplasm: Both recombinant and Fc fusion FLT3L formats demonstrated significant expansion of DCs in healthy volunteers [22,23,40] and, in combination with adjuvants, can potentially promote T cell-mediated anti-tumor activity in cancer patients.